Nurofen rebuts class action
March 2, 2016
NUROFEN manufacturer Reckitt
Benckiser (RB) has defended its
position relating to the class action
by Bannister Law (PD yesterday).
The legal firm is managing a class
action compensation claim for a
refund and damages for customers
who bought Nurofen specifically
labelled for different pains such as
back, period, migraine or tension
headache, with Bannister saying
it believes customers were misled
into buying the more expensive
products believing they could
achieve targeted pain relief.
While Reckitt Benckiser didn’t
wish to comment on the current
proceedings, it has clarified that
Nurofen pain-specific packs contain
ibuprofen lysine which is absorbed
faster than regular ibuprofen and
can thus provide faster pain relief.
“All Nurofen products which
have the same active ingredient,
the same format and the same
formulation have the same
manufacturer’s recommended
retail price (MRRP),” RB said.
The Australian Competition and
Consumer Commission (ACCC)
ordered the removal of the Nurofen
Pain Specific Range of products
from retail shelves starting in
December last year along with
other stipulations, and RB has
confirmed they are in the process
of fulfilling those requirements.
The company also said it is
developing interim packaging as
agreed with the ACCC, more clearly
disclosing to consumers that the
products are equally effective for
other forms of pain.
The Nurofen specific-pain range
were originally labelled Nurofen
Back Pain, Nurofen Period Pain,
Nurofen Migraine Pain, and
Nurofen Tension Headache, each
with its own distinctive colour
themed packaging.
The new packaging, still retaining
the colour themes, clearly states
that the product as well as being
effective for the nominated specific
pain, is “equally effective” for each
of the other named specific pains.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Mar 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Mar 16
